Catamaran recent pullback overdone, says Jefferies Jefferies views the recent sell-off in shares of Catamaran as overdone as it believes concerns over the company's ability to meet 2014 consensus estimates are fully priced in at current levels. The firm keeps a Buy rating on the stock with a $65 price target.
Catamaran to acquire Salveo Specialty Pharmacy for $260M in cash Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.